Board of Directors
Thomas A. Albright
President and CEO, Board Director
Mr. Albright was formerly Chairman and CEO of Andrew Technologies LLC from 2011 to 2017. In the past, Mr. Albright was President of the topical aesthetic division at Syneron Medical Ltd. and before that Head of North American marketing at Nobel Biocare. From 2000 to 2008, Mr. Albright was VP BOTOX Global Strategic Marketing at Allergan, where he led the U.S. launch of BOTOX Cosmetic and the commercial development of Latisse. He started his medical industry experience in 1983 at Parke-Davis division of Warner Lambert, where he was a Director of Marketing on the Lipitor launch team. Mr. Albright was also a Board director of Bonti Inc. prior to its acquisition by Allergan. Mr. Albright has a BS in biology from The Citadel and an MBA in marketing from Mercer University.
Milind K. Ambe M.D.
Board Director, Chairman of the Scientific Advisory Board
Dr. Ambe is a board certified Plastic Surgeon with over 20 years of experience in Newport Beach, California. He is the founder and CEO of the Newport Center Surgical, a multispecialty surgery center of excellence. He is also the founder Ambe Aesthetics, a non-surgical aesthetic center of excellence. Dr. Ambe is also the Chairman of the Company’s Scientific Advisory Board. He graduated Magna Cum Laude from the University of California and received his medical degree with honors from the University of California Medical School in Irvine, California. He has authored several articles in Plastic Surgery including the “The Latest Advances in Aesthetic Plastic Surgery.”
David F. Hale
Chairman of the Board, Founder
Mr. Hale is Chairman of Hale BioPharma Ventures, LLC, a private investment fund. He is also; Chairman of Adigica Health, Biocept, Cassiopea, Clarify Medical, Colorescience, Conatus, Dermata, MDRejuvena, Neurelis and Neurana Pharmaceuticals. In the non-profit world, Mr. Hale is Chairman at Rady Children’s Institute for Genomic Health; Director of Rady Children’s Hospital, the Salk Institute, CONNECT and BIOCOM. He is the former Chairman of Crisi, Santarus, SkinMedica, Micromet, and Somaxon; and a former President and CEO of CancerVax, Gensia and Hybritech.
Mark J. Kerslake
Mr. Kerslake is Principal of the Province Group, a Newport Beach, CA real estate development and investment company active in the acquisition, entitlement, management, and disposition of residential and mixed-use real estate projects in multiple states. Mr. Kerslake has considerable experience in transactional structuring, financial engineering and high-level negotiations with buyers, sellers, lenders and institutional financial partners. Mr. Kerslake holds a MBA from UCLA.
Edward Knowlton, M.D.
Founder, Chief Scientist & Board Director
Dr. Knowlton is a board certified Plastic Surgeon with over 30 years of experience and is a graduate of Washington University Medical School in St. Louis. As the founder of Thermage (a publicly traded company), he was the principle inventor and developer of the ThermaCool TC System that tightens skin non-invasively. Dr. Knowlton has authored over 100 medical device patents and has published several articles on Plastic Surgery including an innovative approach to Breast Reconstruction called “The Peg Procedures.”
Founder, Board Director
Ms. McCarthy is President and CEO of Cross Tack, Inc. a consulting firm providing clients a framework to address critical strategic decisions. She was previously Retired, President and CEO of SM&A, the world’s largest contract procurement service for defense, homeland security, health care, aerospace and information technology. Ms. McCarthy was also previously CFO of PIA Merchandising; Giant Group, Ltd.; and Wherehouse Entertainment. She began her career at Mellon Bank, where she became a Vice President in the Highly Leveraged Transaction Division.
Christoph Westphal, M.D., PhD
Dr. Westphal is a co-founder and Partner of the Longwood Fund. Dr. Westphal was co-founder, CEO, and lead investor of six biotech companies that have completed IPOs: Momenta, Alnylam, Acceleron Pharmaceuticals, Sirtris (acquired by GSK), Verastem, and Flex. He co-founded two additional companies that completed IPOs: Concert Pharmaceuticals, and OvaScience. He also co-founded Alnara (acquired by Lilly), and Axial. Dr. Westphal’s companies have created substantial shareholder value, with aggregate market capitalization of over $15 billion, and have contributed to the creation of over 1,000 jobs. Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University.